



European Food Safety Authority



 **DAVID** 
ALCANTAR SANCHEZ

davidalcantardr@gmail.com

Consolidated list of Article 13 health claims List of references received by EFSA

Part 3IDs 2001 – 3000

Parma, 5 April 2011

- . ID 2318: “Phaseolus Vulgaris (Kidney bean) - Olea europa (Olive) - Rosemarinus officinalis (Rosemary) extracts - OXY-08” and “Weight loss management, fat metabolism & storage improvement”
- . 1 Cecil KM, Lin A, Ross BD, Egelhoff JC, 2002.
Methylsulfonylmethane observed by in vivo proton magnetic resonance spectroscopy in a 5-year-old child with developmental disorder: effects of dietary supplementation. J Comput Assist Tomogr, 26, 818-820.
- . 2 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007.
A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci, 4, 45-52.
- . 3 Ebisuzaki K, 2003. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res, 23, 453-458.

- . 4 Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF, 2006. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. *Osteoarthritis Cartilage*, 14, 286-294.
- . 5 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The Anti-obesity Effect and the Safety of Taking "Phaseolamin 1600 Diet". *J New Rem & Clin*, 54.

153

- . 6 Landa M, 2006. Letter to Charles J. Raubichek (Frommer Lawrence & Haug LLP): PHASE-2® (Phaseolus vulgaris) Pharmachem Laboratories, Inc. Structure/Function Claims. Department of Health and Human Services, U.S.A.
- . 7 Layer P, Zinsmeister AR, DiMagno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- . 8 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem*, 250, 8030-8037.
- . 9 Micol V, Blanes C, Caturla N, Laporta O, Edeas B, 2005. Synergetic mixed nutritional ingredients enhance and maintain weight loss in humans. *AgroFOOD Indus High Tech*, 5, 13-16.
- . 10 Ninapharm, 2008. OXYLIA®. Ingredient description, composition certificate.
- . 11 Ninapharm, 2008. Ingredient mechanisms of actions: OXYLIA® a powerful and safe balancing diet supplement.
- . 12 Ninapharm, 2008. OXYLIA®. Certificate of non toxicity - Test LD5.
- . 13 Ninapharm, 2008. OXYLIA® enhances and mantains weight loss in humans.
- . 14 Ninapharm, 2008. OXYLIA®. Reduction of calorie absorption study done on rats.

- . 15 Ninapharm, 2008. SOD-like activity of OXYLIA®.
- . 16 Pari L and Venkateswaran S, 2003. Effect of an aqueous extract of *Phaseolus vulgaris* on the properties of tail tendon collagen of rats with streptozotocin-induced diabetes. *Braz J Med Biol Res*, 36, 861-870.
- . 17 Raubicheck CJ, 2006. Letter to Mitchell Skop (Pharmachem Laboratories, Inc.): Pharmachem's PHASE-2 STARCH NEUTRALIZER®. FDA-Accepted Weight Control and Starch Digestion Claims. Frommer Lawrence & Haug LLP.
- . 18 Rougier Y, 2005. Solutions Minceur et Contrôle durable du poids - Intérêt scientifique d'une nouvelle génération de compléments nutritionnels respectant les S.L.I.M. data. *Entretiens de Bichat Thérapeutique*, 125-131.
- . 19 Santimone M, Koukiekolo R, Moreau Y, Le Berre V, Rouge P, Marchis-Mouren G, Desseaux V, 2004. Porcine pancreatic alpha-amylase inhibition by the kidney bean (*Phaseolus vulgaris*) inhibitor (alpha-AI1) and structural changes in the alpha-amylase inhibitor complex. *Biochim Biophys Acta*, 1696, 181-190.
- . 20 Tatsutaka Y, Takayo S, Tooru S, 2006. Safety and weight reduction effects of foods containing *Phaseolus vulgaris*. *Eastern Medicine*, 21, 41-47.
- . 21 Venkateswaran S, Pari L, Saravanan G, 2002. Effect of *Phaseolus vulgaris* on circulatory antioxidants and lipids in rats with streptozotocin-induced diabetes. *J Med Food*, 5, 97-103.
- . ID 2104: "Phaseolus vulgaris (Common Name : White bean)" and "Glucose metabolism"
- . 1 Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS, 1982. Starch blockers--their effect on calorie absorption from a high-starch meal. *N Engl J Med*, 307, 1413-1416.
- . 2 Carlson GL, Li BU, Bass P, Olsen WA, 1983. A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man. *Science*,

219, 393-395.

- . 3 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007. A Dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci*, 4, 45-52.
- . 4 Garrow JS, Scott PF, Heels S, Nair KS, Halliday D, 1983. A study of 'starch blockers' in man using ^{13}C - enriched starch as a tracer. *Hum Nutr Clin Nutr*, 37, 301-305.
- . 5 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The anti-obesity effect and the safety of taking PhaseolaminTM 1600 diet. *J New Rem & Clin*, 54.
- . 6 Layer P, Carlson GL, DiMagno EP, 1985. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. *Gastroenterology*, 88, 1895-1902.
- . 7 Layer P, Rizza RA, Zinsmeister AR, Carlson GL, DiMagno EP, 1986. Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus. *Mayo Clin Proc*, 61, 442- 447.
- . 8 Layer P, Zinsmeister AR, DiMagno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- . 9 Lee SC, Gepts PL, Whitaker JR, 2002. Protein structures of common bean (*Phaseolus vulgaris*) alpha- amylase inhibitors. *J Agric Food Chem*, 50, 6618-6627.
- . 10 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem*, 250, 8030-8037.
- . 11 Pari L and Venkateswaran S, 2003. Effect of an aqueous extract of *Phaseolus vulgaris* on plasma insulin and hepatic key enzymes of glucose metabolism in experimental diabetes. *Pharmazie*, 58, 916-919.

- . 12 Pari L and Venkateswaran S, 2004. Protective role of *Phaseolus vulgaris* on changes in the fatty acid composition in experimental diabetes. *J Med Food*, 7, 204-209.
- . 13 Raubichek C, 2006. Letter: Re Pharmachem's PHASE 2 STARCH NEUTRALIZER®: FDA -Accepted weight control and starch digestion claims.
- . 14 Sawada S, Takeda Y, Tashiro M, 2002. Primary structures of alpha- and beta-subunits of alpha-amylase inhibitors from seeds of three cultivars of *Phaseolus* beans. *J Protein Chem*, 21, 9-17.
- . 15 Ternes W, Täufel A, Tunger L, Zobel M, 2005. *Lebensmittel-Lexikon*. Behr's Verlag, Hamburg.
- . 16 Thom E, 2000. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. *J Int Med Res*, 28, 229-233.
- . 17 Udani J, Hardy M, Madsen DC, 2004. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. *Altern Med Rev*, 9, 63-69.
- . 18 Watzl B and Leitzmann C, 1999. *Bioaktive Substanzen in Lebensmitteln*. Hippokrates, Stuttgart.
- . 19 Watzl B and Rechkemmer G, 2001. Flavonoide. *Ernährungs-Umschau*, 48, 498-502.

79

ID 2105: “*Phaseolus vulgaris* (Common Name : White bean)” and “Weight control”

- . 1 Boivin M, Zinsmeister AR, Go VL, DiMagno EP, 1987. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. *Mayo Clin Proc*, 62, 249-255.
- . 2 Boivin M, Flourie B, Rizza RA, Go VL, DiMagno EP, 1988. Gastrointestinal and metabolic effects of amylase inhibition in

diabetics. *Gastroenterology*, 94, 387-394.

- . 3 Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG, 2007. A Dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci*, 4, 45-52.
- . 4 Elmadfa I and Leitzmann C, 1988. *Ernährung des Menschen*. Eugen Ulmer Verlag, Stuttgart.
- . 5 Hahn A, Ströhle A, Wolters M, 2005. *Ernährung–Physiologische Grundlagen, Prävention, Therapie*. Wissenschaftliche Verlagsgesellschaft GmbH, Stuttgart.
- . 6 Harikumar KB, Jesil AM, Sabu MC, Kuttan R, 2005. A preliminary assessment of the acute and subchronic toxicity profile of phase2: an alpha-amylase inhibitor. *Int J Toxicol*, 24, 95-102.
- . 7 Jenkins DJ, Wolever TM, Taylor RH, Barker HM, Fielden H, 1980. Exceptionally low blood glucose response to dried beans: comparison with other carbohydrate foods. *Br Med J*, 281, 578-580.
- . 8 Kasper H and Wild M, 2000. *Ernährungsmedizin und Diätetik*. Urban & Fischer, München.
- . 9 Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y, 2005. The anti-obesity effect and the safety of taking "PhaseolaminTM 1600tm diet. *J New Rem & Clin* 54, 1-16.
- . 10 Layer P, Carlson GL, DiMagno EP, 1985. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. *Gastroenterology*, 88, 1895-1902.
- . 11 Layer P, Zinsmeister AR, DiMagno EP, 1986. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology*, 91, 41-48.
- . 12 Le Berre-Anton V, Bompard-Gilles C, Payan F, Rouge P, 1997. Characterization and functional properties of the alpha-amylase inhibitor (alpha-AI) from kidney bean (*Phaseolus vulgaris*) seeds.

Biochim Biophys Acta, 1343, 31-40.

- . 13 Leitzmann C, Müller C, Michel P, Brehme U, Hahn A, Laube H, 2001. Ernährung in Prävention und Therapie. Hippokrates, Stuttgart.
- . 14 Marshall JJ and Lauda CM, 1975. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. J Biol Chem, 250, 8030-8037.
- . 15 Raubicheck C, 2006. Letter: Re Pharmachem's PHASE 2 STARCH NEUTRALIZER®: FDA -Accepted weight control and starch digestion claims.
- . 16 Shivaraj B, Sharma KK, Pattabiraman TN, 1979. Natural plant enzyme inhibitors: Part VII--Alpha amylase inhibitors & amylases in plant tubers. Indian J Biochem Biophys, 16, 52-55.
- . 17 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- . 18 Tormo MA, Gil-Exojo I, Romero de Tejada A, Campillo JE, 2004. Hypoglycaemic and anorexigenic activities of an alpha-amylase inhibitor from white kidney beans (*Phaseolus vulgaris*) in Wistar rats. Br J Nutr, 92, 785-790.
- . 19 Udani J, Hardy M, Madsen DC, 2004. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev, 9, 63-69.
- . 20 van Wyk BE, 2005. Handbuch der Nutzpflanzen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.



DAVID
ALCANTAR SANCHEZ

davidalcantardr@gmail.com